Personalisation of Aspirin Adjuvant Therapy in Patients with Colorectal Cancer [ 2018 - ]

Research Grant

Researchers: A/Pr Oliver Sieber (Principal investigator) ,  Prof Eva Segelov ,  Prof John Simes

Brief description Aspirin use is associated with a reduced risk of bowel cancer recurrence. However, benefit appears limited to a subset of patients, and some individuals experience side effects. We will analyse tumour samples from patients participating in the ASCOLT clinical trial of aspirin to identify molecular features that can predict who will benefit from aspirin. Predictive biomarkers would be of substantial clinical utility for guiding treatment, minimising toxicity and improving disease outcomes.

Funding Amount $762,580.00

Funding Scheme Project Grants

Notes Standard Project Grant